JP2002508320A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002508320A5 JP2002508320A5 JP2000538687A JP2000538687A JP2002508320A5 JP 2002508320 A5 JP2002508320 A5 JP 2002508320A5 JP 2000538687 A JP2000538687 A JP 2000538687A JP 2000538687 A JP2000538687 A JP 2000538687A JP 2002508320 A5 JP2002508320 A5 JP 2002508320A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- statin
- kit
- mevastatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 27
- 150000003839 salts Chemical class 0.000 description 21
- 239000011780 sodium chloride Substances 0.000 description 21
- AJLFOPYRIVGYMJ-INTXDZFKSA-N Mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 20
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 19
- SEERZIQQUAZTOL-ANMDKAQQSA-N Cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 18
- -1 carboxyalkyl ether Chemical compound 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 11
- 229950009116 Mevastatin Drugs 0.000 description 11
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 10
- 229960002965 Pravastatin Drugs 0.000 description 10
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 10
- 229960005110 cerivastatin Drugs 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 10
- 229960003765 fluvastatin Drugs 0.000 description 10
- 229960004844 lovastatin Drugs 0.000 description 10
- 229960002855 simvastatin Drugs 0.000 description 10
- VDSBXXDKCUBMQC-VUOWKATKSA-N (4S,6R)-6-[(E)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@@H]2OC(=O)C[C@@H](O)C2)=C1 VDSBXXDKCUBMQC-VUOWKATKSA-N 0.000 description 9
- 229950003040 Dalvastatin Drugs 0.000 description 9
- VXDSGTRNDFHIJB-QQPOVDNESA-N [(1S,4aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2S)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 9
- 206010062060 Hyperlipidaemia Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 230000003143 atherosclerotic Effects 0.000 description 6
- 229960005370 atorvastatin Drugs 0.000 description 6
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 6
- SDMBRCRVFFHJKR-UHFFFAOYSA-N 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound OC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O SDMBRCRVFFHJKR-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic Effects 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 230000000271 cardiovascular Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 201000001320 atherosclerosis Diseases 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- 210000004351 Coronary Vessels Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000004432 carbon atoms Chemical group C* 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000000055 hyoplipidemic Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 229960001770 Atorvastatin calcium Drugs 0.000 description 1
- 210000001715 Carotid Arteries Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000001340 slower Effects 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6937597P | 1997-12-12 | 1997-12-12 | |
| US60/069,375 | 1997-12-12 | ||
| PCT/US1998/024679 WO1999030704A1 (en) | 1997-12-12 | 1998-11-20 | Statin-carboxyalkylether combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002508320A JP2002508320A (ja) | 2002-03-19 |
| JP2002508320A5 true JP2002508320A5 (US07560449-20090714-C00011.png) | 2006-01-19 |
Family
ID=22088573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000538687A Pending JP2002508320A (ja) | 1997-12-12 | 1998-11-20 | スタチン−カルボキシアルキルエーテル配合物 |
Country Status (30)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ502874A (en) * | 1997-12-12 | 2004-03-26 | Warner Lambert Co | Antihyperlipidemic statin-lp(a) inhibitor combinations |
| US6861555B2 (en) | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| US20030105154A1 (en) | 2001-10-24 | 2003-06-05 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| IL141953A0 (en) * | 1998-09-30 | 2002-03-10 | Warner Lambert Co | Method for preventing or delaying catheter-based revascularization |
| US6562864B1 (en) * | 1999-09-02 | 2003-05-13 | Drake Larson | Catechin multimers as therapeutic drug delivery agents |
| IN191580B (US07560449-20090714-C00011.png) * | 1999-12-17 | 2003-12-06 | Ranbaxy Lab Ltd | |
| AP2002002587A0 (en) | 2000-01-25 | 2002-09-30 | Warner Lambert Co | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith. |
| AU2001256278A1 (en) * | 2000-04-18 | 2001-10-30 | Bayer Aktiengesellschaft | Use of cse inhibitors for treating heart failure |
| MXPA02009662A (es) * | 2000-04-26 | 2003-03-10 | Warner Lambert Co | Agentes antihipertensivos y su uso. |
| US6689807B1 (en) | 2000-06-08 | 2004-02-10 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | HMG CoA reductase inhibitors for promoting angiogenesis |
| US6777552B2 (en) | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
| IL160077A0 (en) * | 2001-08-16 | 2004-06-20 | Teva Pharma | Processes for preparing calcium salt forms of statins |
| US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| MX367352B (es) | 2012-01-06 | 2019-08-16 | Gemphire Therapeutics Inc | Metodos para reducir el riesgo de padecer una enfermedad cardiovascular. |
| SG11201803442UA (en) * | 2015-11-06 | 2018-05-30 | Gemphire Therapeutics Inc | Treatment of mixed dyslipidemia |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
-
1998
- 1998-11-12 NZ NZ503982A patent/NZ503982A/en unknown
- 1998-11-20 JP JP2000538687A patent/JP2002508320A/ja active Pending
- 1998-11-20 PT PT98960278T patent/PT1045691E/pt unknown
- 1998-11-20 DE DE69828442T patent/DE69828442T2/de not_active Expired - Lifetime
- 1998-11-20 WO PCT/US1998/024679 patent/WO1999030704A1/en not_active Application Discontinuation
- 1998-11-20 PL PL98341066A patent/PL341066A1/xx unknown
- 1998-11-20 AU AU15915/99A patent/AU754089B2/en not_active Ceased
- 1998-11-20 DK DK98960278T patent/DK1045691T3/da active
- 1998-11-20 HU HU0004547A patent/HUP0004547A3/hu unknown
- 1998-11-20 IL IL13534998A patent/IL135349A0/xx unknown
- 1998-11-20 EP EP98960278A patent/EP1045691B1/en not_active Expired - Lifetime
- 1998-11-20 AT AT98960278T patent/ATE285762T1/de not_active IP Right Cessation
- 1998-11-20 ES ES98960278T patent/ES2230733T3/es not_active Expired - Lifetime
- 1998-11-20 KR KR1020007006355A patent/KR20010033003A/ko not_active Application Discontinuation
- 1998-11-20 CA CA002304612A patent/CA2304612A1/en not_active Abandoned
- 1998-11-20 BR BR9813542-2A patent/BR9813542A/pt not_active Application Discontinuation
- 1998-12-09 HN HN1998000185A patent/HN1998000185A/es unknown
- 1998-12-10 CR CR5926A patent/CR5926A/es not_active Application Discontinuation
- 1998-12-10 MY MYPI98005579A patent/MY118381A/en unknown
- 1998-12-10 ZA ZA9811348A patent/ZA9811348B/xx unknown
- 1998-12-11 GT GT199800196A patent/GT199800196A/es unknown
- 1998-12-11 AR ARP980106321A patent/AR017851A1/es unknown
- 1998-12-11 CO CO98073828A patent/CO4970816A1/es unknown
- 1998-12-11 PE PE1998001207A patent/PE20000017A1/es not_active Application Discontinuation
- 1998-12-11 UY UY25299A patent/UY25299A1/es not_active Application Discontinuation
- 1998-12-11 SV SV1998000146A patent/SV1998000146A/es not_active Application Discontinuation
- 1998-12-11 PA PA19988464601A patent/PA8464601A1/es unknown
-
2000
- 2000-04-14 IS IS5445A patent/IS2150B/is unknown
- 2000-06-09 NO NO20002966A patent/NO20002966D0/no not_active Application Discontinuation
- 2000-06-09 CU CU20000140A patent/CU20000140A7/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002508320A5 (US07560449-20090714-C00011.png) | ||
| JP2002501887A5 (ja) | アルツハイマー病の治療用の薬剤の製造のための血漿トリグリセライドレベル低下剤の使用 | |
| RU2003126184A (ru) | Комбинации активатора (активаторов) рецептора, активируемого пролифератором пероксисом (рапп), и ингибитора (ингибиторов) всасывания стерина и лечение заболеваний сосудов | |
| JP2004521894A5 (US07560449-20090714-C00011.png) | ||
| JP2005504092A5 (US07560449-20090714-C00011.png) | ||
| RU2003126187A (ru) | Применение замещенных азетидинонов для лечения ситостеролемии | |
| JP2004532868A5 (US07560449-20090714-C00011.png) | ||
| CA2456732A1 (en) | Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor | |
| JP2004517916A5 (US07560449-20090714-C00011.png) | ||
| Moghadasian et al. | Pharmacotherapy of hypercholesterolaemia: statins in clinical practice | |
| EP1045691B1 (en) | Statin-carboxyalkylether combinations | |
| JP2007512347A5 (US07560449-20090714-C00011.png) | ||
| RU2007149337A (ru) | Новый способ лечения гиперлипидемии | |
| RU2351329C2 (ru) | Ингибиторы кинуренин 3-гидроксилазы для лечения диабета | |
| JP2003524582A5 (US07560449-20090714-C00011.png) | ||
| US8557835B2 (en) | Statin-carboxyalkylether combinations | |
| RU2018133690A (ru) | Лечение пациентов с гомозиготной семейной гиперхолестеринемией, получающих липидоснижающую терапию | |
| Kastelein | The future of lipid-lowering therapy: the big picture | |
| JP2002506818A5 (US07560449-20090714-C00011.png) | ||
| JP2002525321A5 (ja) | カテーテルによる血管再生を予防または遅らせる医薬組成物の製造のためのコレステロール低下剤の使用 | |
| JP2005522490A5 (US07560449-20090714-C00011.png) | ||
| ZA200102230B (en) | Method for preventing or delaying catheter-based revascularization. | |
| JPWO2006090756A1 (ja) | 脂質代謝異常、肥満および糖尿病の新規な予防または治療剤およびそのための使用 | |
| EP1358879A1 (en) | Antilipemic agents | |
| AU2003244047A1 (en) | Antihyperlipidemic stain-Lp(a) inhibitor combinations |
